Ten‐year prognosis of heart failure in the community: follow‐up data from the Echocardiographic Heart of England Screening (ECHOES) study

Abstract

AimsThis study investigates the 10-year survival in the ECHOES (Echocardiographic Heart of England Screening) study and examines factors associated with prognosis. Methods and resultsA prospective study was carried out to investigate 10-year survival in those with heart failure (HF) and/or left ventricular systolic dysfunction (LVSD). The mean age of participants in ECHOES was 64, and 50% were male. Records of all 6162 screened participants were flagged, and deaths up to 25 February 2009 were coded. Causes of death were categorized according to diagnosis on death certificate. Kaplan -Meier curves and log rank tests were used to compare survival times of participants with HF and LVSD in different diagnostic groups. A Cox proportional hazards regression model was used to identify variables associated with risk of death. A total of 2062 of the 6162 (33.5%) participants had died at the census date in February 2009. Of these deaths, 902 (43.7%) were due to cardiovascular disease, including 263 (12.8%) due to HF. Ten-year survival was 75% for participants without HF, 26.7% for those with HF, 37.6% for those with LVSD, and 27.4% for those with HF and LVSD. Multiple-cause HF had a 10-year survival of 11.6%. Multiple variables including diabetes, valvular disease, diuretic use, and a previous label of HF, as well as lifestyle factors such as smoking and obesity, were associated with increased risk of death. ConclusionsPatients with HF and LVSD have a poor prognosis. However, the mortality rates of all-cause, all-stage HF as measured in the ECHOES cohort are around half those reported for patients diagnosed for the first time with HF during hospital admission.--

Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population

“…Despite improvements in therapy and management its global prevalence is rising, rendering HF a serious health problem with a 5-year mortality of around 50% and a 10-year mortality of around 75% [1,2].…”

The REFER (REFer for EchocaRdiogram) study: a prospective validation and health economic analysis of a clinical decision rule, NT-proBNP or their combination in the diagnosis of heart failure in primary care

“…The CDR and NT-proBNP results were also used to determine whether heart failure was likely to be present -the 'test disease' -and referral for echocardiography would have been indicated. Observed compared with test disease status was then cross-tabulated to determine the sensitivity and specificity, positive predictive value (PPV) and negative predictive value (NPV) for the CDR, NT-proBNP and CDR and NT-proBNP in combination and also by the NT-proBNP cut-off points of 125 pg/ml and 400 pg/ml suggested by the ESC 4 and NICE 5 guidelines, respectively; 95% confidence intervals (CIs) were calculated using the binomial exact method. Receiver operating characteristic (ROC) curves were generated to determine the overall discriminatory ability of each test in predicting a diagnosis of heart failure.…”

“…[3][4][5] Making an accurate and timely diagnosis is crucial and requires referral for objective testing but deciding who to refer can be challenging. 6 The symptoms of heart failure are often non-specific and include gradual-onset breathlessness, fatigue and ankle swelling.…”

Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies

“…Despite significant advancements in pharmacological and interventional treatment options, heart diseases represent an increasingly common disorder that carries a poor long-term prognosis [2,3]. Although current approaches improve symptoms and decelerate adverse cardiac remodeling, they fail to address the underlying problem of an irreversible loss of cardiac tissue.…”